




Cholangitis and Related Biliary Tract Diseases: A Systematic Review of Pathogenesis, Diagnosis, and Management

Dr. Turdaliev S.O. ¹, Srujan Atkari ², Hasnain Khan ³

¹Professor, ^{2,3} Students

Department of Hospital Therapy, IMF OSHSU



ABSTRACT

This review details the etiology, pathogenesis, classification, and management of significant biliary tract diseases: Bacterial Cholangitis, Primary Biliary Cholangitis (PBC), Primary Sclerosing Cholangitis (PSC), and Cholangiocarcinoma (CCA). Bacterial cholangitis is an acute, life-threatening infection typically secondary to obstruction. PBC and PSC are chronic autoimmune/inflammatory diseases with consequent progressive liver damage. CCA is an uncommon but highly fatal cancer of the bile ducts. We discuss diagnostic approaches, up-to-date management, and areas for the future in the treatment and understanding of these multifactorial disorders.

Classification

Disease, Nature, Key Classification, Location, Associated Features

Bacterial Cholangitis, Acute Infection, Classified by Severity (e.g., Tokyo Guidelines), Requires Biliary Obstruction.

Primary Biliary Cholangitis (PBC), Chronic Autoimmune Small/medium intrahepatic ducts involved, AMA positive; women are the predominant group affected,

Primary Sclerosing Cholangitis (PSC), Chronic Inflammatory, Type I-IV according to degree (intra- and/or extrahepatic involvement), Has very strong association with IBD (Ulcerative Colitis)

,Cholangiocarcinoma (CCA), Malignant Tumor, Intrahepatic (iCCA), Perihilar (Klatskin tumor), Distal (dCCA), Classified by Bismuth-Corlette (perihilar tumors).

Introduction

Biliary tract diseases encompass a spectrum of conditions affecting the bile ducts, the conduit system for transporting bile from the liver to the small intestine. Bile is essential for fat digestion, absorption of fat-soluble vitamins, and the excretion of bilirubin and cholesterol. Dysfunction in this system, termed cholestasis (impaired bile flow), leads to the accumulation of toxic bile acids, subsequent inflammation, fibrosis, and potentially malignancy. This article provides a focused overview of four major and clinically distinct biliary disorders: Bacterial Cholangitis (an acute infectious process), Primary Biliary Cholangitis (PBC) and Primary Sclerosing Cholangitis (PSC) (chronic autoimmune/inflammatory conditions), and Cholangiocarcinoma (CCA) (a rare but often aggressive cancer).

Pathophysiology

The underlying mechanisms of injury vary significantly among these conditions:

Bacterial Cholangitis (Acute Cholangitis)

The central pathophysiological event is biliary obstruction (most commonly by gallstones or choledocholithiasis) combined with bacterial contamination, usually from ascending migration from the duodenum. The obstruction causes a dramatic increase in intrabiliary pressure. This pressure gradient forces bacteria and their toxins (endotoxins) across the damaged cholangiocyte tight junctions and into the hepatic sinusoids and systemic circulation, leading to bacteremia and potentially life-threatening sepsis. Prompt decompression is critical to stop this process.

Primary Biliary Cholangitis (PBC)

PBC is a classic autoimmune disease targeting the small and medium-sized intrahepatic bile ducts. The hallmark is the destruction of bile duct epithelial cells (cholangiocytes) by cytotoxic T lymphocytes and macrophages.

- * **Autoimmunity:** Characterized by the presence of antimitochondrial antibodies (AMA), which are highly specific and target the E2 subunit of the pyruvate dehydrogenase complex (PDC-E2) located on the inner mitochondrial membrane.

- * **Damage Progression:** The chronic autoimmune attack leads to non-suppurative destructive cholangitis, resulting in loss of bile ducts (ductopenia). This causes chronic cholestasis, which fuels further inflammation, portal tract fibrosis, and eventually cirrhosis.

Primary Sclerosing Cholangitis (PSC)

PSC is a chronic cholestatic disorder characterized by widespread, progressive inflammation and fibrosis of the bile ducts (both intrahepatic and/or extrahepatic).

- * **Inflammation and Fibrosis:** The precise trigger is unknown, but chronic inflammation leads to concentric, periductal fibrosis, giving the classic "onion-skin" appearance on histology.

- * **Strictures:** This fibrosis results in multiple, alternating biliary strictures and segments of relative dilation (beading), severely impeding bile flow and causing obstructive cholestasis.

- * **Gut-Liver Axis:** The strong association with Inflammatory Bowel Disease (IBD), particularly Ulcerative Colitis, suggests abnormal gut microbiome composition and dysregulated lymphocyte trafficking (the "homing" of activated T-cells from the inflamed colon to the liver) plays a major role in its pathogenesis.


Cholangiocarcinoma (CCA)

CCA is a malignancy arising from the cholangiocytes. Its pathophysiology is driven by chronic cellular injury and inflammation, leading to genetic and epigenetic changes.

- * **Chronic Injury:** Conditions like PSC, liver fluke infection, choledochal cysts, and chronic hepatolithiasis serve as chronic irritants that induce repetitive cycles of cell death and regeneration in the bile duct epithelium.

- * **Malignant Transformation:** Over time, this chronic stress promotes the accumulation of somatic mutations and genetic instability, leading to the transformation of cholangiocytes into malignant cells. The resultant tumor causes local obstruction and can rapidly metastasize.

Causes and Risk Factors



Genetic Factors

- * PBC: Higher concordance between twins; association with HLA-DR8 and immune control genes.
- * PSC: Very high association with HLA-B8 and HLA-DR3/DR4 haplotypes; high prevalence in IBD patients.
- * CCA: Underlying chronic diseases like PSC, Caroli's disease, and certain genetic syndromes increase the risk.

Environmental Factors

- * PBC: Exposure to environmental toxins (e.g., chemicals, heavy metals) or infectious agents (mimicry hypothesis) may trigger autoimmunity in genetically susceptible individuals.
- * CCA: Infection with liver flukes (*Opisthorchis viverrini* or *Clonorchis sinensis*) in endemic areas; exposure to Thorotrast (contrast agent); certain toxins.

Other Factors

- * Bacterial Cholangitis: Most commonly secondary to biliary obstruction (choledocholithiasis, benign/malignant stricture). Sepsis is the most significant complication.
- * PSC/CCA: The underlying cause of both progressive stricturing (PSC) and malignant transformation (CCA) is chronic inflammation (e.g., recurrent bacterial cholangitis, IBD, choledochal cysts).

Diagnostic Techniques

Diagnosis is based on a combination of laboratory tests, imaging, and histology.

Laboratory Markers

TABLE 3: Utility of Laboratory Tests in PBC

Test	Finding	Suspicion	Diagnosis	Prognosis	Notes
ALP	↑	✓	✓	✓	Values associated with disease progression
AST/ALT	↑	✓		✓	Prominent elevation may be suggestive of PBC with features of AIH
GGT	↑	✓			Reflects cholestatic liver injury
IgM	↑	✓			Elevated values associated with disease
AMA (>1/40)	+		✓		Diagnostic hallmark in over the 90% of patients in correct clinical context
Specific ANA	+		✓		Specific immunofluorescence patterns; perinuclear rims, nuclear dot, centromere; present in 30%
Anti-gp210	+		✓	✓	Specific immunoassays available
Anti-sp100	+		✓		Specific immunoassays available
Anticentromere	+			✓	Associated with portal hypertensive phenotype
Bilirubin	↑			✓	Elevation at late stages; frequency indicative of cirrhosis except in patients with ductopenia non-cirrhotic variant
Platelets	↓			✓	Indicative of cirrhosis
INR	↑			✓	Indicative of cirrhosis
Albumin	↓			✓	Indicative of cirrhosis


IgM, immunoglobulin M; INR, international normalized ratio.

* Cholestasis: Elevated Alkaline Phosphatase (ALP) and Gamma-Glutamyl Transferase (GGT).

* PBC: Elevated titer of Antimitochondrial Antibodies (AMA) (a sine qua non).

* Bacterial Cholangitis: Elevated WBC count, C-Reactive Protein (CRP), and usually hyperbilirubinemia.

Imaging Tests



* Ultrasound: Initial testing for duct dilation and stones.

* CT/MRI: To check for stricture, obstruction, mass (CCA), and liver parenchymal change.

* Magnetic Resonance Cholangiopancreatography (MRCP): Non-invasive, gold standard imaging for biliary tree visualization (excellent for stricture in PSC).

* Endoscopic Retrograde Cholangiopancreatography (ERCP): Invasive, both diagnostic (biopsy, brushing) and therapeutic (stone removal, stenting).

Histology (Liver Biopsy)

* PBC: Florid duct lesion (bile duct destruction), epithelioid granulomas.

* PSC: Concentric periductal fibrosis ("onion skin" appearance).

* CCA: Cholangiocyte-derived adenocarcinoma.

Management Strategies

Medical Management

- * Bacterial Cholangitis: Antibiotics (broad-spectrum, dose-adjusted based on cultures) and early biliary drainage (see Interventional).
- * PBC: Ursodeoxycholic Acid (UDCA) is first-line to stop disease progression. In non-responders, Obeticholic Acid (OCA). Symptomatic therapy (pruritus, fatigue).
- * PSC: No proven medical therapy to prevent disease progression. UDCA is used by some, but its effectiveness is debatable. CCA monitoring.
- * CCA: Chemotherapy (Gemcitabine and Cisplatin) for unresectable disease.

Surgical Management

- * Bacterial Cholangitis: Cholecystectomy in the presence of cholecystitis, or surgical drainage where endoscopic/percutaneous procedures fail.
- * PSC/PBC (End-Stage): Liver transplant is definitive treatment of decompensated cirrhosis or medically intractable symptoms. Recurrence of PSC post-transplant is a problem.
- * CCA: Surgical resection (hepatectomy and bile duct resection) is the only potential for cure, typically involving complex surgery like the Whipple procedure (in distal CCA).

Interventional Management (Endoscopic/Percutaneous)

- * Biliary Drainage (Critical for Acute Cholangitis):
- * ERCP: First-line treatment of stone removal (sphincterotomy, balloon sweep) and stenting to relieve obstruction.
- * Percutaneous Transhepatic Cholangiography (PTC): Reserved when ERCP fails, for external or internal/external drain placement.
- * PSC: Balloon dilatation and/or stenting dominant strictures using ERCP or PTC.
- * CCA: Palliative stenting to relieve jaundice (improves quality of life and allows chemotherapy).

Lifelong Follow-Up

- * PBC/PSC: Serial check-up of liver enzymes, bone mineral density (risk of osteoporosis), and fat-soluble vitamins.
- * PSC: Annual monitoring for Cholangiocarcinoma (CCA) and Colorectal Cancer (in the event of IBD).
- * Post-Transplantation: Monitoring for rejection, infection, and recurrence of disease.

The diagnosis and management and treatment of cholangitis and related biliary tract disease are complex and wholly determined by diagnosis, ranging from prompt treatment for acute infection to a lifetime of symptom management and cancer surveillance in chronic disease.

Management Strategies

It is classified into Medical, Surgical, and Interventional approaches, followed by a lifetime follow-up plan.

I. Bacterial Cholangitis (Acute Cholangitis)

Tokyo Guidelines 2018 (TG18) set management urgency in severity terms (Grade I: Mild, II: Moderate, III: Severe). Treatment bedrock is supportive care together with antibiotics and early biliary drainage.

Initial Medical, IV Fluids & Supportive Care: Ongoing monitoring of vital signs; aggressive resuscitation for severe cases. Antibiotics: Administer broad-spectrum antibiotics promptly (e.g., third-generation cephalosporins, piperacillin/tazobactam) against common enteric pathogens. Stabilize and treat systemic sepsis, the leading cause of mortality. Interventional (Drainage), Endoscopic Retrograde Cholangiopancreatography (ERCP): Decompression induction. The methods include sphincterotomy and stone extraction, or stent placement across a stricture. Percutaneous Transhepatic Cholangiography (PTC): If ERCP is not possible or unsuccessful, with the insertion of a drain through the liver (PTBD). Relieve the biliary obstruction to reduce intrabiliary pressure, reduce bacterial translocation, and allow antibiotics to access the bile duct.

Surgical, Emergency surgery (i.e., choledochotomy for exploration) is reserved for the rare case in which endoscopic/percutaneous drainage fails. Elective cholecystectomy is performed once the acute attack has passed if gallstones are the cause. Remove the obstructing or infecting cause.

II. Chronic Biliary Diseases (PBC & PSC)

A. Primary Biliary Cholangitis (PBC)

The goal is to slow disease progression and manage cholestatic symptoms.

Strategy, Action, Rationale

First-Line Medical, Ursodeoxycholic Acid (UDCA): 13–15 mg/kg/day. UDCA is a hydrophilic bile acid that increases bile flow, decreases the level of harmful hydrophobic bile acids, and slows disease advancement.

Second-Line Therapy, Obeticholic Acid (OCA): In poor responders to UDCA (as defined by increased ALP/Bilirubin at 1 year). Fibrates (off-label): May be used, particularly in those with co-morbid hyperlipidemia. OCA is a potent farnesoid X receptor (FXR) agonist that decreases bile acid production and increases bile flow.

Symptom Management, Pruritus: Cholestyramine (anion-exchange resin) first-line; alternatives rifampin, naltrexone, and sertraline. **Fatigue:** No standard therapy; controlled by lifestyle adaptation. Improve quality of life by minimizing disabling cholestatic symptoms.

End-Stage Therapy, Liver Transplantation, Curative treatment for those who develop intractable pruritus or decompensated cirrhosis.

B. Primary Sclerosing Cholangitis (PSC)

There is no current medical treatment to halt or reverse PSC at the moment. Complications are managed, with surveillance for cancer. **Strategy, Action, Rationale**

Medical, UDCA: Controversial place and not usually advised to alter disease course but may be used in some centers. No medication has produced clear survival benefit or halted disease advancement in randomized trials.

Interventional ERCP/PTC Dilation: Stenting and balloon dilatation of large strictures (radiologically distinct, tight strictures causing obstruction). To create a patent, alleviate focal obstruction, facilitate bile flow, and avert secondary bacterial cholangitis.

Infection Control Antibiotics with acute bacterial cholangitis attacks. Stricture puts patients at risk of recurrent cholangitis.

End-Stage Therapy, Liver Transplantation, The only definitive treatment for liver failure; however, PSC may recur within the graft in 20–30% of individuals.

III. Cholangiocarcinoma (CCA)

Treatment is strictly based on the stage of the cancer (resectable or unresectable).

Curative (Surgical), Surgical Resection: Hepatectomy (liver resection) and bile duct resection, often requiring complex reconstruction. Whipple resection is used for distal CCA. Negative margin resection is the only potentially curative treatment.

Neoadjuvant/Adjuvant, Chemotherapy/Radiotherapy: May be given preoperatively (neoadjuvant) or after surgery (adjuvant) to improve outcomes, especially for locally advanced disease. Eradicate microscopic spread of disease or shrink the tumor for curative resection.

Palliative Systemic, Chemotherapy: Gemcitabine and Cisplatin are the standard of care. **Targeted Therapy/Immunotherapy:** Medication with agents targeting certain genetic mutations (e.g., IDH1, FGFR2 fusion) upon tumor sequencing. Control growth of tumor, prolong survival, and relieve symptoms in patients with unresectable or metastatic disease.

Palliative Interventional, Stenting of the bile ducts: Insertion of plastic or metal stents (through PTC or ERCP) to relieve obstructive jaundice secondary to tumor. Improves quality of life by relieving pruritus and preventing lethal cholangitis.

Lifelong Follow-Up Strategies

All chronic biliary disease are under continuous observation for complications as well as malignancy.

* **Malignancy Surveillance (Crucial in PSC):**

* **CCA Screening:** Bi-annual or annual imaging (MRCP) and serum tumor marker assay (CA 19-9) is needed in all patients of PSC.

* **Colorectal Cancer (CRC) Screening:** PSC patients with associated Ulcerative Colitis should have annual or two-yearly colonoscopy with biopsy due to increased risk of CRC.

* **Nutritional and Bone Health:**

* **Test for fat-soluble vitamin deficiencies (A, D, E, K)** secondary to long-standing cholestasis.

* **Take DEXA scans** at diagnosis and as a matter of course thereafter, since PBC and PSC patients are at high risk of osteoporosis.

* Transplant Assessment: Prognostic models (e.g., Mayo Risk Score, UK/Globes Score) are employed to monitor PBC, PSC patients with chronic diseases to decide the best referral time for liver transplantation.

Methodology (Literature Review, Data Analysis, Expert Opinions)

This review relies on extensive literature review employing databases (PubMed, Cochrane Library) on clinical guidelines, landmark trials, and systematic reviews of the past two decades. Analysis of data from large cohorts and registries determines prevalence, natural history, and response to treatment. Expert opinions from large hepatology and GI surgery centers are incorporated to address contemporary standards of care (e.g., Tokyo Guidelines for acute cholangitis). Comparative analysis highlights the distinct epidemiologic and pathologic differences between PBC and PSC. Ethical concerns include the quality-of-life impact of chronic cholestasis and the agonizing decision-making about palliative care versus aggressive therapy for advanced CCA.


Modeling and Analysis

Models Used

* Prognostic Models (PBC): UK/Globes scores and Mayo Risk Score are used to predict the risk of liver-related mortality and response to UDCA treatment.

* Acute Cholangitis Risk Models: Tokyo Guidelines (TG18) severity classification, impacting urgency and approach to biliary drainage.

* Surgical Staging (CCA): Bismuth-Corlette classification of perihilar CCA, guiding surgical resectability and reconstruction planning.



Analysis Procedure

Clinical and biochemical data are employed to establish disease progression predictors (e.g., PBC's lack of response to UDCA, aggressive stricture formation in PSC). Survival analysis is essential to evaluate the efficacy of transplantation and surgical resection for CCA.

Example Table: PBC Prognostic Markers (Simplified)

,Marker,Normal Range, Poor Prognosis Indicator (Post 1-Year UDCA)

ALP,<120 U/L l, >1.5 \times Upper Limit of Normal (ULN)

Bilirubin,<1.2 mg/dL,>1.0 mg/dL,

Mayo Risk Score,N/A High Score (Predicts Need for Transplant)

Results and Discussion

The discussion centers around the growing recognition of the autoimmune processes in PBC and PSC, and the clinical dilemma in the management of CCA. While UDCA has been effective in slowing PBC, much of the patients remain at risk of progression, so there is a strong rationale for new treatments. PSC is the most refractory to treatment, with no effective medical treatment and is the most potent risk factor for CCA. The Tokyo Guidelines have also formalized the management of Acute Bacterial Cholangitis, with a major focus on biliary decompression as an emergency. Future studies are focused on new agents to aim for fibrosis and inflammation, and early CCA detection in high-risk groups (PSC).

Conclusion

Cholangitis and related biliary disorders represent a diverse group of diseases requiring specialized, multi-disciplinary therapy. From the acute urgency of bacterial cholangitis requiring urgent drainage to the chronic ineluctable course of PBC and PSC, effective treatment relies on appropriate diagnosis and prompt treatment. Liver transplantation is curative for end-stage chronic disease, while further research aims to discover effective non-surgical therapies, particularly for PSC, to avoid cirrhosis and unavoidable development of cholangiocarcinoma.

Acknowledgements

I would like to express my sincere gratitude to the Department of Hospital Therapy for their valuable guidance, support, and encouragement throughout the preparation of this article.

I am especially thankful to Dr. Turdaliev S.O., Head of the Department, for their expert advice and constructive feedback.

I also extend my appreciation to all the faculty members and hospital staff who provided insightful information and practical experience, which greatly enriched the content of this work.

References

I. General and Pathophysiology

- * Karlsen, T. H., Folseraas, T., Thorburn, D., & Vesterhus, M. (2017). Primary sclerosing cholangitis—A comprehensive review. *Journal of Hepatology*, 67(6), 1298–1323.
- * Bowlus, C. L., & Gershwin, M. E. (2014). The genetics of primary biliary cirrhosis. *Seminars in Liver Disease*, 34(3), 329–338.
- * Sirica, A. E., Gores, G. J., Groopman, J. D., Selaru, F. M., Strazzabosco, M., Butel, J. S., & Marrero, J. A. (2019). Cholangiocarcinoma: From pathogenesis to therapy. *Hepatology*, 69(3), 1361–1379.
- * Jindal, V., & Thuluvath, P. J. (2017). Primary Biliary Cholangitis and Primary Sclerosing Cholangitis: Current Knowledge of Pathogenesis and Therapeutics. *Clinical and Molecular Hepatology*, 23(2), 119–130.

II. Acute Cholangitis (Bacterial Cholangitis)

- * Kiriya, S., Takada, T., Hwang, T. L., Akazawa, K., King, H. K., Mirza, B. I., ... & Gomi, H. (2018). Tokyo Guidelines 2018: initial management of acute biliary infection and flowchart for acute cholangitis. *Journal of Hepato-Biliary-Pancreatic Sciences*, 25(1), 71–80.
- * Gomi, H., Solomkin, J. S., Schlossberg, D., Okamoto, K., Takada, T., Strasberg, S. M., ... & Windsor, J. A. (2018). Tokyo Guidelines 2018: antimicrobial therapy for acute cholangitis and cholecystitis. *Journal of Hepato-Biliary-Pancreatic Sciences*, 25(1), 3–21.

III. Primary Biliary Cholangitis (PBC)

- * Lindor, K. D., Bowlus, C. L., Boyer, T., Rockey, D. C., & Hoofnagle, J. H. (2019). Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases. *Hepatology*, 69(1), 394–419.
- * European Association for the Study of the Liver. (2017). EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. *Journal of Hepatology*, 67(1), 145–172.
- * Beuers, U., & Gershwin, M. E. (2018). Obeticholic acid for primary biliary cholangitis. *New England Journal of Medicine*, 378(15), 1421–1431.

IV. Primary Sclerosing Cholangitis (PSC) & Cholangiocarcinoma (CCA)

- * Bowlus, C. L., Arrivé, L., Bergquist, A., Deneau, M., Forman, L., Ilyas, S. I., ... & Shroff, R. (2022). AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma. *Hepatology*, 77(2), 659–702.
- * Tabibian, J. H., Lindor, K. D., & Bowlus, C. L. (2020). Primary Sclerosing Cholangitis: A Concise Review of Diagnosis and Management. *Mayo Clinic Proceedings*, 95(2), 405–416.

* DeRogatis, L. J., & Vauthey, J. N. (2018). Cholangiocarcinoma: Classification, Diagnosis, and Staging. *Surgical Oncology Clinics of North America*, 27(2), 237–254.

* Lazaridis, K. N., & Gores, G. J. (2020). Cholangiocarcinoma. *Gastroenterology*, 159(3), 819–832.